1. Control of Acute Respiratory Tract Infections(ARI)
Dr. Nadia Aziz
C.A.B.C.M.
Department of Community Medicine
Baghdad Medical College

2. Objectives
1- Determine the causative agents that cause the ARI. 2- Identify the burden of ARI on the community. 3- Identify the causative agent of viral influenza, its occurrence. 4- The ways to prevent and control the occurrence of an epidemic.

3. Introduction
ARI responsible for 20% of childhood (< 5 years) deaths
ARI mortality highest
– HIV-infected
– in children under 2 year of age
– Malnourished
– Weaned early
– Poorly educated parents
– Difficult access to healthcare

4. Introduction
- Most young children worldwide have 4 to 8 episodes of respiratory infections per year. - Incidence of acute lower respiratory infections (pneumonia) is very high in developing countries - Four millions child die each year due to ARI.

5. Anatomical classification
Upper respiratory tract infection 1- Pharangitis 2- Tonsillitis 3- Sinusitis 4- Otitis media 5- Laryngotracheobronchitis 6- Epiglositis

6. Anatomical classification
Acute lower respiratory tract infection 1- Bronchiolitis 2- pneumonia

7. Risk factors Malnutrition Low birth weight Absence of breast feeding
Vitamine A defficency
Indoor air pollution
Low socioeconomic status
Poor hygiene
Missing EPI vaccination

8. Etiological agents Viruses Bacteria Streptococcus pneumonia
Para influanzae virus
Respiratory syncytial virus
Influenza virus
Bacteria
Streptococcus pneumonia
Haemophilus influanzae

9. INFLUENZA ICD-10 J10, J11 Identification
An acute viral disease of the respiratory tract characterized by:
fever, headache, myalgia, prostration, coryza, sore throat and cough.
Cough is often severe and protracted.
other manifestations are self-limited in most patients, with recovery in 2–7 days.

10. INFLUENZA Differential Diagnosis
Influenza may be clinically indistinguishable from disease caused by other respiratory viruses and undifferentiated acute respiratory disease.

11. INFLUENZA
Influenza derives its importance from: - The rapidity with which epidemics evolve - The widespread morbidity - The seriousness of complications(viral and bacterial pneumonias). - Emergence among humans of influenza viruses with new surface proteins can cause pandemics

12. INFLUENZA High risk group Severe illness and death occur among:
- The elderly
- Debilitated by chronic cardiac, pulmonary, renal or metabolic disease.
- Anemia or immunosuppression.

13. Complication Reye syndrome
- Involving the CNS and liver, is a rare but serious complication following virus infections in children who have ingested salicylates.
- Children and teenagers recovering from chickenpox or flu-like symptoms should never take aspirin.

14. Diagnosis
Isolation of influenza viruses from pharyngeal or nasal secretions or washings on cell culture or in embryonated eggs.
Direct identification of viral antigens in nasopharyngeal cells and fluids (FA test or ELISA).
Rapid diagnostic tests
Viral RNA amplification (used to identify small amounts of  RNA in test samples)

15. Infectious agents
Three types of influenza virus are recognized: A, B and C. Type A includes 15 subtypes of which only 2 (H1and H3) are associated with widespread epidemics. Type B is infrequently associated with regional or widespread epidemics. Type C with sporadic cases and minor localized outbreaks.

16. Infectious agents
The antigenic properties of the 2 relatively stable internal structural proteins, the nucleoprotein and the matrix protein, determine virus type.

17. Infectious agents
Influenza A subtypes are classified by the antigenic properties of surface glycoproteins: Hemagglutinin (H) Neuraminidase (N). Frequent mutation of the glycoproteins of influenza A and influenza B viruses results in emergence of new variants.

18. Infectious agents Pandemics results from:
1- Emergence of completely new subtypes at irregular intervals (only for type A) results from antigenic shift in HA gene
Minor antigenic changes (antigenic drift) of A and B viruses responsible for frequent epidemics and regional outbreaks and require annual reformulation of influenza vaccine.

19. Infectious agents
Pandemics 2- Unpredictable recombination of human and mammalian or avian antigens.

20. INFLUENZA Occurrence As pandemics (rare), epidemics (almost annual),
localized outbreaks and sporadic cases.
Ranking as global health emergencies (pandemic e.g. 1918, 1957, 1968) with millions of deaths (40 million in 1918).

21. INFLUENZA
Influenza viral infections with different antigenic subtypes also occur naturally in swine, horses, mink and seals, and in many other domestic species in many parts of the world. Aquatic birds are a natural reservoir and carrier for all influenza virus subtypes.

22. INFLUENZA Reservoir Humans are the primary reservoir
for human infections.
Birds and mammalian
reservoirs such as swine

23. INFLUENZA
Mode of transmission
Airborne spread

24. INFLUENZA
Incubation period
Short, usually 1–3 days.

25. INFLUENZA Susceptibility
impact of epidemics and pandemics depend upon: level of protective immunity in the population, strain
virulence, extent of antigenic variation of new viruses and number of previous infections.
Pandemics (emergence of a new subtype): Total population immunologically naive

26. Methods of control A. Preventive measures:
1) Educate the public and health care personnel in basic personal hygiene, especially transmission via unprotected coughs and sneezes, and from hand to mucous membrane.

27. Vaccine
2) Immunization with Inactivated and live virus vaccines may provide 70%–80% protection against infection in healthy young adults. Live vaccines, used in the Russian Federation for many years, registered for intranasal application in healthy individuals aged 5–49.

28. Vaccine
In the elderly Inactivated vaccines may reduce severity of disease and incidence of complications and deaths.

29. Vaccine
Two doses more than 1 month apart are essential for children under 9.
Routine immunization programs directed towards:
- Those at risk of serious complications or death
- Those who might spread infection (health care personnel and household contacts of high-risk persons).
- Immunization of children on aspirin treatment to prevent development of Reye syndrome.

30. Vaccine Contraindications: Allergic hypersensitivity to egg protein
or other vaccine components is a contraindication.

31. Chemoprophylaxis
3) Effective chemoprophylaxis of influenza A: Amantadine hydrochloride (CNS side-effects) Rimantadine hydrochloride

32. Chemoprophylaxis
Oseltamivir have been shown to be safe and effective for both prophylaxis and treatment of influenza A and B.

33. B. Control of patient, contacts and the immediate environment
1) Report to local health authority: Reporting outbreaks or laboratory-confirmed cases Class 1.

34. Control of patient, contacts and the immediate environment
In epidemics isolate patients (especially infants and young children)

35. Control of patient, contacts and the immediate environment
Protection of contacts: A specific role has been shown for antiviral chemoprophylaxis with amantadine or rimantadine against type A strains

36. Control of patient, contacts and the immediate environment
Specific treatment: Amantadine or Rimantadine started within 48 hours of onset of influenza A illness and given for approximately 3–5 days in 2 divided doses

37. Control of patient, contacts and the immediate environment
During treatment with either drugs, drug-resistant viruses may emerge late in the course of treatment and be transmitted to others.

38. Epidemic Measures
- health care personnel should be immunized annually. - Maintaining adequate supplies of antiviral drugs would be desirable to treat high-risk patients and essential personnel in the event of the emergence of a new pandemic strain for which no suitable vaccine is available in time for the initial wave.

39. Thank You & Good Luck